Introduction
Cholangiocarcinomas (CCCs) are malignancies arising from the biliary ductal system with an annual incidence of approximately 2000 to 3000 cases in the United States and a 2:1 male to female predominance. 1 Unfortunately, more than 90% of these cancers are not curable by resection at presentation. CCCs are classified into 3 types, depending on anatomic location: intrahepatic, perihilar, or extrahepatic. Perihilar CCCs, also known as Klatskin's tumor, are the most common, followed by extrahepatic; the least common type is the intrahepatic variants. Gallbladder cancer is also classified as a CCC but will be excluded from this discussion.
Tumorigenesis
CCC arises from biliary epithelial cells. Most (more than 90%) are adenocarcinomas, while the rest are squamous cell carcinomas. The exact etiology is unclear, but chronic inflammation of the bile ducts, as seen with primary sclerosing cholangitis (PSC) or with chronic parasitic infections, has been known to induce hyperplasia, abnormal cellular proliferation, and subsequent dysplastic changes, as seen particularly in the Asian population. The more common etiological factors for CCC are outlined in Table 1 .
Staging
Intrahepatic CCC is staged according to the TNM classification for liver cancers ( Table 2) . Extrahepatic CCC (both proximal perihilar and distal intraductal) is staged according to the TNM classification based on the depth of penetration of the bile duct wall and the involvement of adjacent structures, regional lymph node spread, and distant organ metastases ( Table 2 ). 2 Since intrahepatic CCCs are staged as liver cancers, their survival rate is similar to liver cancers as well, whereas stage I extrahepatic CCCs, which are confined to the bile duct mucosa or muscularis propria, have a 2-year survival rate of 27%, and stage IV tumors, which have metastases to adjacent or distant structures, have a less than 4% survival rate. 3
Diagnosis
The most common presenting symptom is painless obstructive jaundice. Other presenting signs include acholic stools, pruritis, dark urine, weight loss, and abdominal pain. Physical examination is limited to presence of jaundice and possibly a palpable gallbladder (Courvoisier sign) if the obstructing tumor is distal to the insertion of the cystic duct into the common bile duct. Laboratory tests are consistent with obstructive jaundice with elevations in alkaline phosphatase and γ glutamyl transferase. There are no specific tumor markers associated with CCC. CA 19-9 levels greater than 100 U/mL have a sensitivity and specificity of 89% and 86%, respectively, in detecting CCC in patients with PSC.
Preoperative Assessment
Unfortunately, more than 90% of CCC is unresectable. A thorough and accurate noninvasive to minimally invasive preoperative evaluation is required to prevent unnecessary laparotomy. Current modalities, including ultrasound, computed tomography scan, and magnetic resonance imaging, can provide information on location and involvement of adjacent and distant organ involvement. Magnetic resonance cholangiography, endoscopic retrograde cholangiopancreatography, and percutaneous transhepatic cholangiography can provide accurate detail on bile duct involvement and can also provide brushing specimen for cytology. Newer modalities such as endoscopic ultrasound and positron emission tomography scan have increased the arsenal used to more accurately delineate the preoperative staging of CCC.
Treatment
Currently, only complete tumor resection offers longterm survival benefit. Patient assessment for resection should be based on the preoperative staging of the disease and patient condition. While surgical resection is the only potentially curative intervention, this has to be tempered against individual patient condition. Possible contraindications to surgical resection can be split into patient-related factors or tumor-related factors. Poor performance status, major cardiopulmonary 
TNM definition for liver cancer
Primary tumor (T) TX: Primary tumor cannot be assessed T0: No evidence of primary tumor T1: Solitary tumor without vascular invasion T2: Solitary tumor with vascular invasion or multiple tumors, none more than 5 cm T3: Multiple tumors more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s) T4: Tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of the visceral peritoneum Regional lymph nodes (N) NX: Regional lymph nodes cannot be assessed N0: No regional lymph node metastasis N1: Regional lymph node metastasis disease, class 4 and higher American Society of Anesthesiologists score, and preexisting cirrhosis are all patient-related factors precluding surgical resection. Tumor-related contraindications are bilateral or multifocal intrahepatic disease, invasion of the portal vein trunk or hepatic artery, bilateral involvement of hepatic arterial or portal venous branches, unilateral hepatic vascular invasion with contralateral ductal spread, and distant metastases.
Surgical Treatment
Treatment options include resection with curative intent, palliative resection, palliative biliary-enteric bypass, and palliative percutaneous, endoscopic, or intraoperative stenting. Resection can be aided by preoperative percutaneous placement of stents. Tumors of the distal and midportion of the common bile duct may require a pancreaticoduodenectomy. Intrahepatic CCC would require hepatic resection similar to hepatocellular carcinoma depending on its laterality of involvement.
In general, the operation begins with an exploratory laparoscopy to rule out obvious carcinomatosis or distant metastases. An upper midline or a chevron-type incision is sufficient for adequate exposure. A thorough exploration is performed, and any enlarged lymph nodes are biopsied and sent for frozen section analysis. Stage III CCC will deem this intervention as palliative. The tumor should be palpated and assessed for proximal and distal extension and portal venous and hepatic arterial invasion. If satisfactory for resection, the tumor in excised, and frozen sections of the margins should be sent to document negative proximal and distal biliary margins. A Roux-en-Y hepatico-or choledochojejunostomy is performed depending on the proximal extent of resection.
Palliative Care
Although surgical resection offers the only hope for cure, most patients are found to have unresectable disease on initial presentation and carry an extremely grim prognosis. This has led to an emphasis on the role of palliative care, with the relief of biliary obstruction being the primary goal in the management of these patients. Surgical bypass was once considered as the primary means of palliating biliary obstruction, but nonsurgical placement of biliary stents is now associated with lower morbidity and mortality and is considered the standard of care.
Adjuvant Therapy
Adjuvant or neoadjuvant chemotherapy has failed to show survival benefit. Currently available nonsurgical therapies include chemotherapy with 5-fluorouracil, mitomycin, methotrexate, and cisplatin; external beam radiation; and transcatheter brachytherapy. Their roles are limited and may show some benefits in control of symptoms. Newer modalities such as photodynamic therapy, brachytherapy, and high-intensity ultrasound therapy may result in improved survival and play a future role as an adjunctive therapy to surgical resection 4 ; however, data continue to be collected, and no conclusive reports from randomized series are yet available.
Summary
CCC is usually diagnosed at an advanced age and has poor survival rates. Signs and symptoms are vague and require a high index of suspicion for biliary malignancy to be investigated promptly. Surgical resection remains the only treatment modality that can provide a potential cure or long-term survival. Palliative resection may provide control of biliary and intestinal obstructive symptoms; however, endoscopic or transhepatic biliary drainage has emerged as the preferred nonoperative method of biliary decompression.
